BBP
CBSE
IBRX
MEME
FDA said: “We’ll take a look”
ImmunityBio just got a fresh catalyst: the FDA accepted its supplemental Biologics License Application for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer. Translation? The agency isn’t approving it yet, but it is officially putting the request on the desk instead of leaving it in the inbox abyss.
The market liked the vibe. Shares were up about 8% in premarket trading, which is basically Wall Street’s way of saying, “Hey, maybe this thing has more room to run.” And with a PDUFA target date of January 6, 2027, this story now has a clear regulatory clock attached to it.
Why investors care
This filing is supported by QUILT 3.032 Phase 2/3 data in 80 patients, and the company says the study hit its primary endpoint with a 12-month disease-free survival rate of 58.2%. The bigger selling point for investors: ANKTIVA plus BCG could widen ImmunityBio’s reach in bladder cancer beyond the version already approved in April 2024 for CIS patients.
The long game
If the FDA eventually says yes, ImmunityBio could have a broader commercial shot at a market where better bladder-preservation options matter a lot. If not, the stock probably gives back some of this optimism real fast — because biotech, as always, loves a dramatic plot twist.
Big picture: this isn’t the finish line, but it is a meaningful checkpoint. For IBRX, the regulatory road just got a lot more visible.